Zobrazeno 1 - 10
of 130 552
pro vyhledávání: '"Edwards P"'
Autor:
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Núria Roca, Ferran Tarrés-Freixas, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Victor Guallar, Bonaventura Clotet, Joaquim Segalés, Jorge Carrillo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P
Externí odkaz:
https://doaj.org/article/417894952ca54f88947455ec8d336df7
Autor:
Carla Usai, Erola Ainsua-Enrich, Victor Urrea Gales, Edwards Pradenas, Cristina Lorca-Oró, Ferran Tarrés-Freixas, Núria Roca, Mónica Pérez, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Julieta Carabelli, Benjamin Trinité, Ester Ballana, Eva Riveira-Muñoz, Nuria Izquierdo-Useros, Bonaventura Clotet, Julià Blanco, Victor Guallar, Guillermo Cantero, Júlia Vergara-Alert, Jorge Carrillo, Joaquim Segalés
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-12 (2024)
Abstract Age is associated with reduced efficacy of vaccines and linked to higher risk of severe COVID-19. Here we determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previo
Externí odkaz:
https://doaj.org/article/f305a783ac09456b913d3b908a30b8e8
Autor:
Leire de Campos-Mata, Benjamin Trinité, Andrea Modrego, Sonia Tejedor Vaquero, Edwards Pradenas, Anna Pons-Grífols, Natalia Rodrigo Melero, Diego Carlero, Silvia Marfil, César Santiago, Dàlia Raïch-Regué, María Teresa Bueno-Carrasco, Ferran Tarrés-Freixas, Ferran Abancó, Victor Urrea, Nuria Izquierdo-Useros, Eva Riveira-Muñoz, Ester Ballana, Mónica Pérez, Júlia Vergara-Alert, Joaquim Segalés, Carlo Carolis, Rocío Arranz, Julià Blanco, Giuliana Magri
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived
Externí odkaz:
https://doaj.org/article/e88c94774f434c16bec8caaf30b4258f
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
Autor:
Lorna Leal, Judit Pich, Laura Ferrer, Jocelyn Nava, Ruth Martí-Lluch, Ignasi Esteban, Edwards Pradenas, Dàlia Raïch-Regué, Antoni Prenafeta, Karla Escobar, Carmen Pastor, Marc Ribas-Aulinas, Benjamin Trinitè, Jordana Muñoz-Basagoiti, Gemma Domenech, Bonaventura Clotet, Júlia Corominas, Aida Corpes-Comes, Carme Garriga, Antonio Barreiro, Nuria Izquierdo-Useros, Joan Albert Arnaiz, Alex Soriano, José Ríos, Marga Nadal, Montserrat Plana, Julià Blanco, Teresa Prat, Elia Torroella, Rafel Ramos, HIPRA-HH-1 study group
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-12 (2023)
Abstract In response to COVID-19 pandemic, we have launched a vaccine development program against SARS-CoV-2. Here we report the safety, tolerability, and immunogenicity of a recombinant protein RBD fusion heterodimeric vaccine against SARS-CoV-2 (PH
Externí odkaz:
https://doaj.org/article/0a20f98d912343ffad1efe821c52c851
Autor:
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Núria Roca, Ferran Tarrés-Freixas, Julieta Carabelli, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Bonaventura Clotet, Victor Guallar, Joaquim Segalés, Jorge Carrillo
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The in
Externí odkaz:
https://doaj.org/article/8d145e1f4f964517b358c973214ef36f
Autor:
Ferran Tarrés-Freixas, Carmen Aguilar-Gurrieri, María Luisa Rodríguez de la Concepción, Victor Urrea, Benjamin Trinité, Raquel Ortiz, Edwards Pradenas, Pau Blanco, Sílvia Marfil, Luis Manuel Molinos-Albert, Ana Barajas, Anna Pons-Grífols, Carlos Ávila-Nieto, Ismael Varela, Laura Cervera, Sònia Gutiérrez-Granados, María Mercedes Segura, Francesc Gòdia, Bonaventura Clotet, Jorge Carrillo, Julià Blanco
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In th
Externí odkaz:
https://doaj.org/article/20b68eeb7d6f4ecfa2c0a0005799608d
Autor:
Eudald Felip, Edwards Pradenas, Margarita Romeo, Silvia Marfil, Benjamin Trinité, Víctor Urrea, Ainhoa Hernández, Ester Ballana, Marc Cucurull, Lourdes Mateu, Marta Massanella, Bonaventura Clotet, Teresa Morán, Julià Blanco
Publikováno v:
Molecular Oncology, Vol 17, Iss 4, Pp 686-694 (2023)
Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influen
Externí odkaz:
https://doaj.org/article/cb23f6b2bc0042d091babfcdf72a34a2
Autor:
Francisco Belda BSc, MS, PhD, Oscar Mora BPharm, Monica Lopez-Martinez PhD, Nerea Torres PhD, Ana Vivanco BSc, Silvia Marfil BSc, Edwards Pradenas PhD, Marta Massanella PhD, Julià Blanco PhD, Rebecca Christie BS, Michael Crowley BBA
Publikováno v:
Plasmatology, Vol 17 (2023)
Vaccines are an important tool in combating the COVID-19 pandemic. Two mRNA vaccines (mRNA-1273 and BNT-162b2) and an adenovirus vector vaccine (Ad26.COV2.S) were among the first vaccines to be approved by global regulatory authorities. The aim of th
Externí odkaz:
https://doaj.org/article/5784d93a91a3451b9625bca989b3aa01
Autor:
Antoni Prenafeta, Gregori Bech-Sàbat, Alexandra Moros, Antonio Barreiro, Alex Fernández, Manuel Cañete, Mercè Roca, Luis González-González, Carme Garriga, Joachim Confais, Marion Toussenot, Hugues Contamin, Andrés Pizzorno, Manuel Rosa-Calatrava, Edwards Pradenas, Silvia Marfil, Julià Blanco, Paula Cebollada Rica, Marta Sisteré-Oró, Andreas Meyerhans, Cristina Lorca, Joaquim Segalés, Teresa Prat, Ricard March, Laura Ferrer
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107224- (2023)
Summary: SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still completely controlle
Externí odkaz:
https://doaj.org/article/9369697d1b964e229177289631f80d99
Autor:
Silvia Garcia-Cirera, Joan Calvet, Antoni Berenguer-Llergo, Edwards Pradenas, Silvia Marfil, Marta Massanella, Lourdes Mateu, Benjamin Trinité, Maria Llop, Marta Arévalo, Carlos Galisteo, Cristóbal Orellana, Rafael Gómez, María Nieves Gómez-Gerique, Inma Carmona, Bonaventura Clotet, Julià Blanco, Jordi Gratacós
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Limited data exists on SARS-CoV-2 sustained-response to vaccine in patients with rheumatic diseases. This study aims to evaluate neutralizing antibodies (nAB) induced by SARS-CoV-2 vaccine after 3 to 6 months from administration in Systemic
Externí odkaz:
https://doaj.org/article/4e0f7fe7af794e2382f8fe911f0bbf38